Alternative probes targeting EGFR include the EGFR affibody (ABY-029), which has completed phase I clinical trials for gliomas, sarcomas, and head and neck cancers (NCT02901925, NCT03154411, NCT03282461) [113], and EGFR nanobodies which have demonstrated tumor labeling in mouse models of head and neck and cervical cancer [114]. The gene discussed is EGFR; the disease is glioma.